Bookmark
Forward
What we have learned from the Xaliproden Sanofi-aventis trials.
P Douillet, J M Orgogozo
The journal of nutrition, health & aging 2009 Apr
Sizes of these terms reflect their relevance to your search.
No abstract available.
Citation
P Douillet, J M Orgogozo.
What we have learned from the Xaliproden Sanofi-aventis trials.
The journal of nutrition, health & aging.
2009 Apr;13(4):365-6
Mesh Tags
Alzheimer Disease
Biomarkers
Humans
Magnetic Resonance Imaging
Naphthalenes
Pyridines
Randomized Controlled Trials as Topic
Research Design
Substances
Biomarkers
Naphthalenes
Pyridines
xaliproden
PMID: 19300882
View Full Text